Medication Access & Pricing
Expert articles and analysis related to medication access & pricing.
AI Summary — Last 30 Days
CMS’s emerging drug-pricing agenda under the Trump administration is moving beyond unit-price negotiations toward payment-model levers: the GENEROUS Medicaid model could reshape supplemental rebate dynamics, but its savings potential remains highly dependent on confidential model terms, existing Medicaid rebate baselines, and state/manufacturer participation incentives (KFF). For VBC stakeholders, the strategic issue is whether drug affordability tools—such as $50 monthly access to selected GLP-1s and broader biosimilar adoption—become embedded into ACO, Medicare value-based payment, and population-health performance economics rather than treated as pharmacy-only initiatives. Health systems and payers are therefore under pressure to integrate pharmacy and medical financials, especially for biosimilars, GLP-1s, and cell/gene therapies, where formulary design, adherence, total cost of care, and quality performance increasingly determine whether value-based contracts actually capture savings (AJMC).
Related Articles
A Look at the GENEROUS Model and Factors That Could Impact Medicaid Drug Costs
This issue brief provides background on the GENEROUS model, examines the factors that will contribute to the model’s overall impact on Medicaid drug costs, and illustrates how savings will depend on m...
GLP-1 coverage costs pressure employers and Medicare plans in 2026
Even as evidence accumulates about the efficacy of GLP-1 drugs, concerns surrounding insurance coverage of the products remain unresolved. Both employers and insurers are trying to navigate the dichot...
Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up.
From newsletter: This Week: There Are Many MAHAs This Week: There Are Many MAHAs Plus, the cost of health care is a more prominent focus for MAHA voters than issues like food and vaccine policy. ͏ ͏ ͏...
A Look at the GENEROUS Model and the Potential Impact on Medicaid Drug Costs
From newsletter: This Week: There Are Many MAHAs This Week: There Are Many MAHAs Plus, the cost of health care is a more prominent focus for MAHA voters than issues like food and vaccine policy. ͏ ͏ ͏...
Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up.
For all Trump’s showmanship, the share of Americans his policies will likely help remains slim, even if some patients do come out ahead.
MFN Drug Pricing Proposal Raises Questions Around Access, Innovation, and Commercial Coverage
Amgen, AbbVie say IRA negotiations impacted Q1 sales
At least two drugmakers say they’re feeling the impact of the Inflation Reduction Act, after the first drug prices negotiated under the law took effect in January. Amgen and AbbVie reported in their...
STAT+: Administration report on most favored nation drug pricing raises new details — and questions
Administration report on most-favored nation drug pricing raises new details — and questions.
Most Favored Nation Drug Pricing: Anchoring To A Moving Target
Most Favored Nation Drug Pricing: Anchoring To A Moving Target Health Affairs
Amgen’s Retreat: Denmark, Repatha, And The Collision Course Of US MFN Pricing Policy
Amgen’s Retreat: Denmark, Repatha, And The Collision Course Of US MFN Pricing Policy Health Affairs